Cargando…
Drug Development for Maternal Health Cannot Be Left to the Whims of the Market
ThePLoS Medicine Editors argue that the current business model of the pharmaceutical industry provides no incentives for the development of new treatments for maternal health, and that political will is needed to support new approaches.
Formato: | Texto |
---|---|
Lenguaje: | English |
Publicado: |
Public Library of Science
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2504051/ https://www.ncbi.nlm.nih.gov/pubmed/18578567 http://dx.doi.org/10.1371/journal.pmed.0050140 |
Ejemplares similares
-
Whims of Hysteria
Publicado: (1885) -
Adaptive Immunodeficiency in WHIM Syndrome
por: Majumdar, Shamik, et al.
Publicado: (2018) -
A chemotaxis model to explain WHIM neutrophil accumulation in the bone marrow of WHIM mouse model
por: Yip, Ai Kia, et al.
Publicado: (2019) -
Genotype–phenotype correlations in WHIM syndrome: a systematic characterization of CXCR4(WHIM) variants
por: Zmajkovicova, Katarina, et al.
Publicado: (2022) -
Pandemic puppies bought on a whim
Publicado: (2020)